Early changes in the gut microbiome among HIV-infected Individuals in Uganda initiating daily TMP/SMX

Carolyne Atugonza¹, Adrian Muwonge², Christine F. Najjuka³, David P. Kateete¹, Eric Katagirya³, Savannah Mwesigwa¹, Benon Asiimwe³

¹Department of Immunology and Molecular Biology, Makerere University, ²Genetics and genomics, Roslin Institute, University of Edinburgh, ³Department of Microbiology, Makerere University,

Corresponding author: Carolyne Atugonza (atugonzacarolyne@gmail.com)

Abstract

Daily cotrimoxazole (TMP/SXT) prophylaxis is part of the HIV treatment package for all new HIVinfected individuals in Uganda. Although this treatment has shown reduced morbidity and mortality in HIV, it remains controversial due to its contribution to developing antibiotic-resistant bacteria. Moreover, the effects of daily use of a broad-spectrum antibiotic on the gut microbiome remain unknown.

To study the early effects, we analysed shotgun metagenome sequence data from stool samples of five newly HIV-infected individuals initiating TMP/SXT prophylaxis longitudinally for the first 30 days of treatment. Using shotgun metagenomics sequencing, we generated both taxonomic and functional profiles from each patient and compared gut microbial changes Pre-TMP/SXT and post-TMP/SXT on Day 5, Day 14, and Day 30.

Daily TMP/SXT prophylaxis resulted in a shift characterised by an enrichment of Prevetollea and Ruminococcus genera members and the depletion of Lactococcus and Bacteroides genera members. Furthermore, these microbial shifts were associated with changes in the functional profile revealed by a differential abundance of pathways of amino acid metabolism, carbohydrate metabolism, and nucleotide biosynthesis linked to members of the Bacteroidaceae and Enterobacteriaceae families.

TMP/SXT daily prophylaxis in HIV-infected individuals is associated with dramatic changes in microbial composition and functional profiles; however, other factors such as Age, Gender, HIV clinical stage, and ART regiment are at play. Further investigation is needed to examine the implication of these shifts on clinical management and outcomes among HIV patients.

Background

The human gastrointestinal tract (GIT) is a complex system made up of a large number of microorganisms. The GIT comprises bacteria, archaea, viruses, parasites, and fungal species(Lu et al., 2018), collectively known as 'gut microbiota. The gut microbiota plays essential physiological functions, including developing and maintaining host immunity, aiding digestion, and helping control pathogenic bacteria (Kau et al., 2011; Thaiss et al., 2016; Liu et al., 2017).

However, during the Human immunodeficiency virus (HIV) infection, this microbial community is highly destabilised, as seen by a reduction in microbial diversity and loss of beneficial bacteria in a phenomenon known as dysbiosis, often characterised by reduced abundances of Bacteroides and increased abundance of genus Prevotella (Zevin et al., 2016). Such altered gut integrity due to HIV infection modifies the gut mucosal barrier resulting in a change in the gut microbiota and a shift to proinflammatory or potentially pathogenic bacterial populations causing opportunistic infections (Dillon, Frank, and Wilson, 2016). Such infections continue to cause significant mortality and morbidity worldwide in HIV-infected individuals. In high-income countries, such conditions are limited, with Pneumocystis jiroveci pneumonia being the most prevalent (Kaplan et al., 1996). On the other hand, low-income countries have a high occurrence of opportunistic infections, including parasitic enteritis and bacterial diseases like tuberculosis and salmonella, mainly affecting HIV-infected individuals (Holmes et al., 2003; Lowe et al., 2013).

Cotrimoxazole treatment or prophylaxis against several of these opportunistic infections is offered alongside antiretroviral therapy (ART). Cotrimoxazole, a fixed-dose combination of sulfamethoxazole and trimethoprim (TMP/SMX), is abroad spectrum antimicrobial agent that targets a range of aerobic gram-positive and negative organisms, fungi, and protozoa (D'Souza et al., 2020). With recommendations from the WHO, TMP/SXT prophylaxis is incorporated into the health care package for all HIV-exposed individuals(WHO, 2014), particularly for areas where malaria and bacterial infections are highly prevalent. In compliance with WHO recommendations, Uganda offers TMP/SXT preventative therapy for a particular category of patients, including all people living with HIV initiating ART, Pregnant and breastfeeding women, children and adolescents aged 15 and below, and all patients suspected to have treatment failure(of Health and Republic of Uganda, 2016). Although WHO guidelines denote changes in the gut microbiome caused by TMP/SMX, studies and details of these changes remain limited, especially in Uganda (WHO, 2014).

Notably, a knowledge gap remains in the understanding of the early effects of TMP/SMX on the gut microbiome in HIV patients. Using the nationally scheduled clinical visit dates in the HIV care program in Uganda; we examined the 30-day longitudinal impacts of TMP/SMX initiation during HIV treatment on the Gut microbiome by utilising shotgun metagenomics. Metagenomics sequencing allows comprehensive sampling of all genes in organisms in a sample (Mardis, 2008). It enables the evaluation of bacterial diversity and abundance of microorganisms, which are missed by cultivation-based methods. Moreover, functional metagenomics can identify novel functional genes, microbial pathways, and dysbiosis of the intestinal microbiome and determine interactions and co-evolution between microbiota and host. This study reports on the gut microbiota taxonomic and functional profiles examined in the study cohort.

MATERIALS AND METHODS

Study Population and Sample

This prospective, preliminary study was conducted to study the effects of TMP/SMX on the gut microbiome in 5 adult HIV-infected patients. The School of Biomedical Sciences Research and Ethics Committee of Makerere University (IRB No.0006291) approved the study. We enrolled newly diagnosed HIV-infected individuals reporting at the Makerere Joint AIDS Project (MJAP) ISS clinic at Mulago Hospital from February 2019 to May 2019. Critical inclusion criteria are as follows; (i) Had

not received any antibiotic treatment in the last 30 days (ii) No comorbidities with infectious agents. All participants provided written informed consent before study enrollment. Upon enrollment, all participants continued with the recommended HIV care package freely provided by the HIV Clinic, including the prescribed ART regimen and TMP/SMX. For TMP/SMX, the prescription was provided based on national guidelines structured according to a patient's weight; <5kg 120mg, 5-14.9kg 240mg, 15-29.9kg 480mg, ≥30kg 960mg. Fresh stool samples were collected from participants during their clinic visit at four different time points, including a baseline sample before TMP/SMX treatment, Day 5, Day 14, and Day 30 after TMP/SMX to study the early effects of TMP/SMX treatment. Samples were frozen within 4-6 hours of collection and stored at -80^oC until analysis. Twenty stool specimens were collected from the five patients during the study.

Stool DNA Extraction and sequencing

According to the manufacturer's instructions, total bacterial DNA was extracted using the Powerlyzer DNA extraction kit (Qiagen Inc., Germany). Total DNA concentration and purity were assessed by absorbance on a Nanodrop N1000 (Thermo Fisher Scientific, Carlsbad, CA, USA) by measuring the A260/A280 ratio before storage at -20^oC. DNA libraries were prepared using Illumina Truseq Nano DNA Library Preparation kits, quantified, and normalised before 20 samples were pooled per sequencing lane. Shotgun metagenomic sequencing was performed using the DNBseq BGI platform at the BGI institute, China, with a sequencing depth of 5 Gbps and an insert size range of 275-450 bp per sample.

Sequence quality assessment

The raw sequencing data were processed using METAWRAP(Uritskiy, DiRuggiero and Taylor, 2018) pipeline to remove low-quality reads, adapters, and human DNA contamination. In brief, reads were trimmed using a length cut-off of 30; subsequent, trimmed reads were then screened against adapter sequences and the human genome sequence with a 90% identity cut-off. After filtering, a mean of 21 million sequences was obtained for every metagenome sample.

Taxonomic and Functional Profiling

For each sample, taxonomic profiling for cleaned reads was obtained using MetaPhlAn2 Software (Segata *et al.*, 2012) and functional profiling using HUMAnN (Franzosa *et al.*, 2018). Sequence data were deposited in the NCBI Sequence Read Archive database.

Statistical Analysis

All statistical analyses were performed using the R program version 3.5.1. Alpha diversity was calculated using normalised counts, and the Kruskal-Wallis test determined the significance. Beta diversity was determined using the Bray-Curtis distance matrix. Principal component analysis (PCoA) was performed on the calculated distance matrixes, and PERMANOVA or Adonis calculated significance with 999 permutations. PCoA plots and confidence ellipses were generated by ggplot and ggpubr version package in R. All P values <.05 were considered statistically significant for all tests.

RESULTS

Clinical and demographic characteristics of the study cohort

Five HIV-infected Ugandan subjects were enrolled in the study at the MJAP HIV clinic at Mulago Hospital. Participants were primarily female, with a median age of 31 and a median body mass index (BMI) of 23.6 kg/m2. During admission to the clinic, patients were also classified according to clinical stages of the WHO (Weinberg and Kovarik, 2010): Stage 1: 3 patients; Clinical Stage 2: 1 patient; Clinical Stage 3; 1 patient, and no patients with clinical stage 4 were enrolled. CD4 count data was also obtained during the enrolment of the study. Four participants had a CD+4 T-cell count of \geq 500 cells/µL, with one participant having a 200-500 cells/µL count and 4 participants \leq 200 cells/µL at the

time of enrolment. All the participants were started on antiretroviral treatment and cotrimoxazole prophylaxis treatment. Three participants were started on TDF/3TC/DTG regimen, while two were started on TDF/3TC/EFV regimen (Table 1).

	Table 1-Baseline characteristics of HIV	patients enrolled in the study	cohort
--	---	--------------------------------	--------

Demographics, median (10R)		All subjects (n = 15)
Age (vears)		31(23-42)
Gender	Male n	1 (40%)
	Female	4 (60%)
Height (cm)	remaie	158 (155 8-166 3)
Weight (kg)		62(575-7175)
$\frac{1}{2} \frac{1}{2} \frac{1}$		$02(37.3^{-7}1.73)$
Divil (Kg/III)		25.0 (21.5- 27.1)
CD4. T cell could (cells (c))		
CD4+ T-Cell count (Cells/µL)	CD4+ 1-cell counts	540 (186-692)
	CD4+ 1-cell counts \geq 500	8 (53.3%)
	CD4+ 1-cell counts 200-500	3 (20%)
	CD4+ T-cell counts < 200	4 (26.7%)
WHO Clinical Stages	Stage I	12 (80%)
	Stage II	1 (6.7%)
	Stage III	2 (13.3%)
	Stage IV	0
Medication		
ART, n		15
ART Regimen	TDF/3TC/DTG	9 (60%)
	TDF/3TC/EFV	6 (40%)
Social conditions		
Residence	Slum	2 (13.3%)
	urban	1 (6.7%)
	Urban-rural	12 (80%)
Education	Primary	5 (33.3%)
	secondary	10 (66.7%)
Marital status	Separated	4 (26.7%)
	married	8 (53.3%)
	single	3 (20%)
Ethnicity n (%)	Muganda	12 (80%)
	Mutooro	1 (6 7%)
	Bwandese	2 (13 3%)
Living conditions	Rwandese	2, (13.370)
Water source p	Communal tan	6 (10%)
water source, in	Direct in	0 (40%)
	Piped in Droto stad well	L (0.7%)
	Protected well	6 (40%)
	Open well	2 (13.3%)
lollet type	Pit latrine	15
Diet	Omnivorous	14 (93.3%)
	Vegetarian	1 (6.7%)
Probiotics intake	Yes	7 (46.7%)
	No	8 (53.3%)
Alcoholic beverages	Yes	6 (40%)
	No	9 (60%)

BMI; Body Mass Index, TDF; Tenofovir Disoproxil fumarate, 3TC; Lamivudine, DTG; Dolutegravir, EFV: Efavirenz, IQR; Interquartile range. Indicated symbol, % indicates percentages

Changes in microbial diversity along the treatment timeline among HIV patients

To investigate the impacts of Early ART treatment with TMP/SMX on the gut microbiome, we longitudinally compared sampled gut microbiome profiles of HIV-infected individuals. Twenty stool samples from 5 HIV-infected individuals were collected longitudinally for up to 4 consecutive weeks.

To examine whether there was an alteration in bacterial composition, we compared alpha diversity before (Pre-TMP/SMX) and after TMP/SMX initiation (Post-TMP/SMX). Post TMP/SMX was associated with decreased α -diversity (P = 0.053, Shannon; P = 0.053) (Figure 1A). When we compared alpha diversity at the different time points, a difference was observed between Baseline and Day 30 after TMP/SMX initiation (Kruskal-Wallis, P =0.056) (Figure 1B). As expected, alpha diversity was lower in samples on Day 5, Day 14, and Day 30 after TMP/SMX administration. Only Age and Gender were associated with significant alpha diversity compared to other metadata. (Supplementary Figure 1S).



Figure 1 Signs of Dysbiosis in HIV-infected individuals initiating TMP/SXT. (A) Alpha diversity (Shannon Index and InvSimpson) before and after TMP/SMX initiation. (B) Comparison of alpha diversities between the different time points showing a difference between Baseline and Day 30. (C) Principal coordinates Analysis (PCoA) of Bray-Curtis distances at the different time points showing clustering patterns according to HIV clinical stages.

The differences between pre and post-TMP/STX suggest an association in gut microbial changes; however, the PCoA using Bray-Curtis distance shows no significant structural changes since no significant clustering at phyla and genera at the different time points (Linear mixed model, Bray-Curtis, R2=0.084, P = 0.941) were observed. On the other hand, the HIV stages were associated with gut microbial structure, explaining up to 36.7% of the structural variation (Adonis; P < 0.05, $R^2 = 0.41186$). Similarly, treatment regimen types were associated with gut microbiome differences, explaining 26.9% of structural variation (Adonis; P < 0.05, $R^2 = 0.30186$) (Figure 1C). Further, multivariable PERMANOVA analysis showed age explained 36%, gender 14 variation in the microbiota composition, indicating that they may be drivers of distinct microbial community composition. In addition, individuals tended to cluster together, suggesting the existence of distinct microbiota unique to individuals despite the same treatment. Other tested variables did not significantly contribute to the variability in microbiota composition (Table 2)

Variable	F.Model	R ²	Pr(>F)
Treatment groups (Pre TMP/STX and Post TMP/STX)	1.225	0.064	0.282
Timepoints	0.496	0.085	0.918
CD4 count	1.180	0.061	0.296
BMI	1.022	0.054	0.378
Age	10.246	0.363	0.001*
Gender	3.000	0.143	0.021*
HIV clinical Stage	4.922	0.367	0.001**
ART Regimen	6.636	0.269	0.002**

Table 2. Permutational multivariate analysis of variance (PERMANOVA) table for microbial
community composition from study groups before and after TMP/STX and associated metadata.

PERMANOVA assessed the significance of associations between Bray-Curtis dissimilarity and the different variables. P-values are based on 999 permutations. * represents significant P values. (P< 0.05)

TMP/SMX treatment and associated changes in gut taxonomic profiles

Here we sought to examine how the microbiota community varied at different time points from the Baseline to Day 5, Day 14, and Day 30. Bacteroides were the most abundant gut phyla among the samples, followed by Firmicutes, Proteobacteria, and Actinobacteria (Figure 2A). A comparison of bacteria at the family level demonstrated abundance in Bacteroidaceae, Prevotellacea, Ruminococcaceae, and Lachnospiraceae (Figure 2C). The top genera included Bacteroides, Prevotella, Eubacterium, Parabacteroides, Feacalibacterium, Ruminococcus, and Roseburia, with Prevotella and *Bacteroides* having the highest abundance (Figure 2B).

We further examined the differential abundance of genera with the progression of time using DESeq2. By accounting for patient differences, results revealed shifts in taxa abundance at the different visit dates. From Baseline until day 30, we observed an enrichment of the Prevotella genus. On day 5, a depletion of the Lactococcus, Clostridium, Ruminococcus, Fusobacterium, and Klebsiella genera was observed. On day 14 and Day 30, a similar trend as on Day 5 was observed with an additional depletion of the Bacteroides genus (Supplementary Table S1).

Further analysis was conducted to examine any changes at the species level. Special abundances at the different time points showed many shifts in OTU abundance that were statistically (FDR < 0.05) significant. Using the Baseline as a reference, two species, Ruminococcus gnavus and Prevotella copri, were significantly enriched on day 5, whereas day 14 revealed Prevotella copri and Bacteroide pectinophilus enrichment. On day 30, a similar trend as on day five was observed (Figure 3). Other Bacteroide caccae, Bacteroides pectinophilus, Barnesiella intestinihominis, species of Clostridium_sCA413, Fusobacterium Mortiferum, Holdemanella biformis, Klebsiella variicola, Lactococcus tauri, RuminococcusCA488 had a significant decrease throughout treatment and did not return to baseline levels. The results reveal a major compositional shift in the microbiota on Day 14 and Day 30 with a significantly increased fold change (FC>10, FDR < 0.05) of some species suggesting a possible impact by antimicrobial treatment.



Figure 2. Early Taxonomic changes in the gut microbiota of HIV-infected individuals initiating TMP/SXT treatment are dominated by Bacteroidetes. Bacteria taxa were identified in stool samples of 5 HIV-infected individuals initiating TMP/SXT treatment and followed up for 30 days using Shotgun metagenomics sequencing. (A) A stacked bar plot analysis showing the top 6 phylum abundances at each time point. (B) Relative abundance of the top genus at the different time points. (C) Comparison of the Abundances of top phyla showing Protobacteria having a statistical difference at the different time points. # Statistical difference was calculated using the Kruskal-Wallis test.





Figure 3. Changes in taxonomic abundance in the gut microbiome Fold change scores determined by DESeq2 analysis reveal differences in the abundance of key Species between different time points. Significant group differences were corrected with Benjamini–Hochberg False Discovery Rate p FDR < 0.05.

Changes in microbial functional profiles following TMP/STX

Next, we further investigated the functional profiles in the gut microbiome during TMP/STX uses to obtain pathway abundance HUMANn2 pipeline. This functional profiling analysis revealed 400 pathways and heatmap analysis of the top 30 pathways across all the samples (Figure 4). Diversity analysis revealed no significant differences between the pathways based on the different time points with Shann (Supplementary Figure 2S).



Figure 4. Inferred functional profile of the Gut microbiome during TMP/SXT administration for 30 days. Heatmap of the top 30 most abundant pathways in the individual samples as recognised by HUMAnN2.

Samples were hierarchically clustered using Bray-Curtis dissimilarity for the pathways and colour-coded based on the time point shown in the image.

In further analysis, we investigated how the metabolic activity changed during treatment. Here, we studied how the pathways changed at each time point about the pathways observed at the baseline time. Using DESeq2 (Figure 4), changes on Day 5 revealed the enrichment of Purine Nucleotide synthesis pathways (Adenosine ribonucleotide de novo biosynthesis and 5-aminoimidazole ribonucleotide biosynthesis pathways) and depletion of Cell wall biosynthesis pathways (peptidoglycan maturation) and Purine Nucleotide Degradation pathways (adenosine nucleotides degradation II and guanosine nucleotides degradation III). On Day 7, enriched pathways included Purine Nucleotide pathways (Adenosine ribonucleotide de novo biosynthesis), Aromatic compound biosynthesis (Chorismate biosynthesis I and super pathway of aromatic amino acid biosynthesis), and Carrier Biosynthesis (Phosphopanthothenate biosynthesis I). Cell wall biosynthesis pathways (peptidoglycan maturation), Sugar derivative degradation (Anhydromuropeptides recycling), and central metabolism pathways (Glycolysis IV) were the most depleted.

Similarly, by Day 30, Purine Nucleotide synthesis pathways (Adenosine ribonucleotide de novo biosynthesis and 5-aminoimidazole ribonucleotide biosynthesis) were enriched. Top depleted pathways included Carrier Biosynthesis pathways (flavin biosynthesis II and factor 420 biosynthesis), Cell wall biosynthesis pathways (peptidoglycan maturation), and aromatic compound biosynthesis (Chorismate biosynthesis I). A summary of depleted and enriched pathways is represented in a table (Supplementary Table S2).

		Regulation Down Up					
		Baseline Vs Day 14		Baseline Vs Day 30	Ba Vs	seline Day 5	
	S-adenosyl-L-methionine cycle I_1 L-lysine biosynthesis VI_2						
	flavin biosynthesis I (bacteria and plants) superpathway of chorismate metabolism						
	L–lysine biosynthesis III L–lysine biosynthesis VI						
	L–lysine biosynthesis III_1 L–lysine biosynthesis VI_1				_		
	adenine and adenosine salvage III_1 adenine and adenosine salvage III_3				-		5
	preQ0 biosynthesis_2 preQ0 biosynthesis_2				_		Am ac
	superpathway of aromatic amino acid biosynthesis_1 chorismate biosynthesis_1						id olisn
	S-adenosyl-L-methionine cycle I S-adenosyl-L-methionine cycle I						_
	chorismate biosynthesis from 3-dehydroquinate superpathway of aromatic amino acid biosynthesis						
	chorismate biosynthesis I preQ0 biosynthesis_3						
	superpathway of aromatic amino acid biosynthesis_2						
	S-adenosyl-L-methionine cycle I_3						
	predu Diosynthesis_1 anhydromuropeptides recycling						
	anhydromuropeptides recycling_2 anhydromuropeptides recycling_1 bexitol fermentation to lactate formate ethanol and acetate 2						
	hexitol fermentation to lactate, formate, ethanol and acetate_1 hexitol fermentation to lactate, formate, ethanol and acetate						deg pa
	Bifidobacterium shunt pentose phosphate pathway (non-oxidative branch)_1				_		ohyd radat elatec thwa
	pentose phosphate pathway (non-oxidative branch) CDP-diacylglycerol biosynthesis I_1			_	_		lirate tion ys
	CDP-dtacylglycerol biosynthesis I adenosine ribonucleotides de novo biosynthesis_5						
	CDP-diacylglycerol biosynthesis_2 adenosine ribonuclentides de novo biosynthesis [_2 adenosine ribonuclentides de novo biosynthesis]						
	peptidoglycan biosynthesis I (meso-diaminopimelate containing)						
	ULIP-N-acetyimuramoyi-pentapeptide biosynthesis II (losine-containing)_1 purine ribonucleosides degradation_1				_		ω
	UDP-N-acetylmuramoyl-pentapeptide biosynthesis II (lysine-containing)_2 supernathway of 5-aminoimidazole ribonucleotide biosynthesis 1						Ce Struc iosyt
	superpathway of 5-aminoimidazole ribonucleotide biosynthesis UDP-N-acetylmuramoyl-pentapeptide biosynthesis II (lysine-containing)						11 ture hesis
	purine ribonucleosides degradation_2 UDP-N-acetyImuramoyl-pentapeptide biosynthesis II (lysine-containing)_3						
	superpathway of 5-aminoimidazole ribonucleotide biosynthesis_2 olvcolvsis IV (plant cvtosol)						
	glycolysis IV (plant cytosol)_2 glycolysis IV (plant cytosol)_1		_				
	CMP-3-deoxy-D-manno-octulosonate biosynthesis I starch degradation V_1					•	m
e	methylerythritol phosphate pathway I_1 starch degradation V						Centr
Nan	phosphopantothenate biosynthesis _1 methylerythritol phosphate pathway i phosphonaythesis L						lism
wav	methylerythritol phosphate pathway I_2 starch deoradation V 2						
Pathv	phosphopantothenate biosynthesis [2						
	peptidoglycan maturation (meso-diaminopimelate containing)_2 peptidoglycan maturation (meso-diaminopimelate containing)_2						_
	factor 420 biosynthesis coenzyme A biosynthesis II (mammalian)_1						Cof Ca Vit
	coenzyme A biosynthesis II (mammalian)_2 CDP-diacylglycerol biosynthesis II_1						nd nthes
	CDP-diacylgi/cerol biosynthesis II coenzyme A biosynthesis II (mammalian) CDP-diacyldycarol biosynthesis II 2						ŝ
	coenzyme A biosynthesis II (mammalian)_3						
	ICA cycle IV (2-oxogiutarate deedcarooxylase) superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass_1 superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass_1		_				nerat of ecurs tabol and
	urate biosynthesis/inosine 5'-phosphate degradation_1						<u>< 78 7</u>
	UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)_1 urate biosynthesis/inosine 5'-phosphate degradation					_	Nuc nucl degn
	urate biosynthesis/inosine 5 - phosphate degradation_3 urate biosynthesis/inosine 5'-phosphate degradation_2 guagosine ribonucleatides de pous biosynthesis 1				_		Ieotic and adati
	guanosine ribonucleotides de novo biosynthesis guanosine ribonucleotides de novo biosynthesis						on le le
	queuosine biosynthesis_1						
	seleno-amino acid biosynthesis quanosine nucleotides deoradation III						
	superpathway of L-phenylalanine biosynthesis_1 superpathway of L-phenylalanine biosynthesis						
	adenine and adenosine salvage III guanosine nucleotides degradation III_2						
	guanosine nucleotides degradation III_1 adenine and adenosine salvage III_4						
	adennine and adenosine salvage III_2 adenosine ribonucleotides de novo biosynthesis_1 IIMP biosynthesis						
	adenosine ribonucleotides de novo biosynthesis_4 UMP biosynthesis_2						
	superpathway of pyrimidine deoxyribonucleoside salvage adenosine ribonucleotides de novo biosynthesis	-					Bio
	adenosine ribonucleotides de novo biosynthesis_6 adenosine ribonucleotides de novo biosynthesis_3				_		ucleo: sythr
	queuosine biosynthesis_4 UMP biosynthesis_4 UMD biosynthesis_4						tide 1esis
	unie uokynttess_1 pyruvate fermentation to isobutanol (engineered)_1 nueunsine biosumbasis				_		
	UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)_2 5-aminoimidazole ribonucleotide biosynthesis I 1						
	5-aminoimidazole ribonucleotide biosynthesis II_1 5-aminoimidazole ribonucleotide biosynthesis I						
	5-aminoimidazole ribonucleotide biosynthesis II pyruvate fermentation to isobutanol (engineered)						
	ישט – איש – acetyimuramoyi–pentapeptide biosynthesis I (meso-diaminopimelate containing) queuosine biosynthesis וואס שישט איש						
	UNUT DIVENTION pyruvate fermentation to isobutanol (engineered)_2 UDP-N-acetylmuramoyl-pentapeotide biosvnthesis I (meso-diaminonimelate containion)						
	5-aminoimidazole ribonucleotide biosynthesis I_2 5-aminoimidazole ribonucleotide biosynthesis I_2						
	· -	-10	20		-10	20	
				Logz Foldonalige			

Figure 5. Differential Abundance analysis reveals fundamental pathway changes during TMP/SXT initiation in HIV-infected individuals. Bar plot of Identified pathways from HUMANn2 showing DESeq2 log2 fold change values for comparisons at the different time points using Baseline as a reference. Pathways represented were grouped into different metabolic classes. Duplicated pathways were reported as two or more bacteria attributed to the pathway's contribution.

Inferring functional taxonomic communities

Data were further analysed to understand which species contributed to the enrichment or depletion of significant functional pathways. The important discriminative pathways enriched between Baseline and day 5 (PWY) were mainly contributed by Butyrivibrio crossotus, one pathway (adenine and adenosine salvage III) by Lachnospiraceae bacterium, and one pathway (adenosine ribonucleotides de novo biosynthesis) by Acidaminococcus fermentans. One species, Shigella sonnei, contributed to all depleted pathways. (Supplementary table). Similarly, on Day 14, enriched pathways were contributed mainly by Butyrivibrio crossotus, and depleted pathways were contributed by Shigella_sonnei and Bacteroides stercoris. By Day 30, enriched pathways were primarily contributed by Butyrivibrio crossotus, and depleted pathways were contributed by three species Shigella sonnei, Bacteroides stercoris, and Barnesiella intestinihominis. These results are consistent with our previous results that showed a high representation of the family Lachnospiraceae, Bacteroidacea, and Barnesiellacea in the gut microbial abundance (Supplementary Figure 3S).

Discussion

In this study, we investigated the early effects of daily TMP/SXT on the gut microbiome of HIV-infected individuals. Patients were followed up for 30 days with samples collected at the Baseline before treatment initiation (Baseline) and at day 5, day 14, and day 30 to study the early effects of TMP/SXT on the gut microbiome taxonomic and metabolic profiles.

Shifts in functional profiles associated with TMP/SXT

Results revealed a varied functional profile at the different time points during treatment with pathways involving Amino acid metabolism, Carbohydrate metabolism, Nucleotide biosynthesis and degradation, cell structure, and cofactor/ carrier/ Vitamin biosynthesis during TMP/SXT treatment.

From Baseline to day 30, we found an enrichment of pathways involved in amino acid metabolism in the gut microbiota. In particular, pathways of chorismate biosynthesis, aromatic amino acid biosynthesis, L-methionine, and adenine and adenosine salvage were upregulated throughout treatment. In contrast, continuous depletion of L-lysine and flavin biosynthesis was observed during treatment. Pathways involved in amino acid metabolism play a role in shaping the response of immune cells (O'Neill, Kishton and Rathmell, 2016). However, Lysine depletion would be of concern as a significant percentage of circulating lysine in the host has been reported to be derived from microbial sources (Metges, 2000).

In addition, we observed the enrichment of the purine nucleotide synthesis pathways, Adenosine ribonucleotide de novo biosynthesis, and 5-aminoimidazole ribonucleotide biosynthesis pathways throughout treatment (Day 30). These pathways involve nucleic acid synthesis, cell signalling, and energetic homeostasis. 5-aminoiamidazole ribonucleotide is the crucial intermediate for purine nucleotide biosynthesis of the gut microbiota (Sheng et al., 2021). The high abundance of these pathways may indicate significant bacterial metabolic activity during growth. In addition, we identified differential abundances of pathways involved in central metabolism and pathways in cofactor, carrier, and vitamin biosynthesis. Pathways altered were responsible for the production of energy and nucleotides. Moreover, this is consistent with studies that have shown bacteria respond to the stress of antibiotics through the diversion of ATP from core metabolic processes to drive the maintenance of ion gradients (Stokes et al., 2019).

Important to note that members of Firmicutes majorly contributed functional roles among bacterial taxa for enriched pathways; Butyrivibrio crossotus, Lachnospiraceae bacterium 2 1 58FAA, Eubacterium siraeum, and Acidaminococcus fermentans. Members of Clostridia are known for their ability to participate in vital metabolic processes, including amino acid fermentation and polysaccharide degradation (Dai, Wu and Zhu, 2011). These taxa are also members of butyrate producers. The association of these observed bacteria suggests that antibiotic exposure promotes an abundance of butyrate-producing *Clostridium* members. On the other hand, depleted pathways were contributed by Proteobacteria member Shigella sonnei and Bacteroidetes members; Bacteroides stercoris and Barnesiella intestinihominis. Further study is needed to examine this microbial functional signature and its role during TMP/SXT.

Subsequently, these findings raise an important consideration of how taxonomic shifts caused by TMP/SXT pressure may simultaneously offer valuable insight into changing active communities. Alterations of such pathways may have important physiological significance due to TMP/SXT impact on the gut, given that the products of such metabolisms, such as short-chain/branched-chain fatty acids and biogenic amines, can cause changes in the intestinal environment (Tremaroli & Bäckhed, 2012); however, more research is warranted. Although these results contribute to understanding the early impacts of TMP/SXT in the gut microbiota, it would be essential to identify which metabolic profiles are genuinely relevant and are a consequence of antibiotic treatment. Moreover, this would provide an opportunity to target which pathways are associated with TMP/SXT treatment to reduce the impact of gut microbiota dysbiosis.

Structural and compositional shifts associated with TMP/SXT

Next, we analysed how TMP/SXT impacted the gut microbial composition. We observed compositional shifts were mainly characterised by an abundance of Bacteroidota, Firmicutes, Proteobacteria, and Actinobacteria at the Phylum level in the gut microbiome of Patients initiating TMP/SXT therapy similar to other studies (Dillon et al., 2014; Monaco et al., 2016; Vujkovic-Cvijin and Somsouk, 2019; Parbie et al., 2021). We did not observe significant phylum level changes with time in the study. At the family level, we reported an abundance in Bacteroidaceae, Prevotellaceae, and Lachnospiraceae, whereas Bacteroides, Prevotella, and Roseburia dominated the genus level, similar to a study by Machiavelli et al. (Machiavelli et al., 2019). The composition shifts at the species level show enrichment of species belonging to Prevetollea and Ruminococcus genera and depletion of species belonging to Lactococcus and Bacteroides genera. Here we note an enrichment in Ruminnococcus gnavus and Prevotella copri. Ruminnococcus gnavus is an anaerobic, gram-positive member of the gut microbiome. Ruminococcus are associated with protective and disruptive roles in the gut by immune modulation through the production of Fatty acid chains (Flint et al., 2008) or its proinflammatory actions as reported in IBD (Png et al., 2010). Moreover, the enrichment with the genus Prevotella has been exhibited in other HIV studies (Vujkovic-Cvijin et al., 2013; Lozupone et al., 2014; Mutlu et al., 2014). Similarly, a study by Kaur et al. 2018 also observed elevated levels of Prevotella copri and its potential inflammatory role in the HIV disease (Kaur et al., 2018). Additionally, we reported a depletion in *Bacteroides caccae* and *Lactococcus tauri*. A said low abundance in several species of the genus Bacteroides has an anti-inflammatory function by promoting T regulatory cell reactivity, and these microorganisms have also been associated with increased inflammation (Pérez-Santiago et al., 2013; Jiang et al., 2017; Lee et al., 2018; Neff et al., 2018; Xie et al., 2021). Decreases in commensals, including Lactococcus, have been reported during HIV infection (McHardy et al., 2013; Mutlu et al., 2014). Lactococcus is also associated with potential benefits to the host by producing bacteriocins and organic acids (Yan Yang et al., 2016). Overall, trends in microbiota have been reported with a signature increase in Prevotella and a decrease in Bacteroides in HIV-infected individuals.

We also found a microbial compositional shift after TMP/SXT initiation associated with a significantly decreased diversity compared to pre-antibiotic use and a microbial shift associated with Age, HIV clinical stage, and ART regimen use. Previous studies support our observation that TMP/SXT use causes compositional changes in the gut during its use(ref). In contrast, a study by Monaco et al.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.07.24315002; this version posted October 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

(Monaco et al., 2016) on HIV individuals using TMP/SXT did not reveal significant changes in the alpha diversity of studied individuals. Important to note is the difference in study design as this study was conducted on individuals on long-term use of TMP/SXT. Thus, although early effects of TMP/SXT may initially impact the alpha diversity, these effects may be resolved over time, as shown in other studies (Raymond et al., 2016; Palleja et al., 2018; Shaw et al., 2019). Similarly, D'zoula et al. (D'Souza et al., 2020) found that infants on TMP/SXT had a reduced β - diversity compared to their non-TMP/SXT counterparts.

Although the CD4+ T cell population is highly depleted during HIV infection, and their loss has been shown to affect the gut microbial structure, for this study negatively, we found no association between CD4+ T cell count and viral load with the microbial composition. This is consistent with Russo et al. (Russo et al., 2022) found a microbiota with unchanged overall bacterial diversity in individuals with HIV-1 infection, before ART and after reaching virological suppression within 24 weeks of ART. In contrast, other studies reported an association of these factors with microbial diversity (Lu et al., 2018; Lyu *et al.*, 2021). Large numbers of our study participants may be necessary to detect such signals. Further work would benefit from relating microbiome differences to more in-depth immune phenotyping of this population.

Our results are also consistent with another study conducted in Mexico that found that PI/r-based regimens had more severe effects than NNRTI-based regimens on gut microbiome diversity and composition (Villanueva-Millán et al., 2017). We identified lower alpha diversity and altered bacterial composition in individuals undergoing PI/r treatment compared to others on NNRTI regimens. Protease inhibitors are known to induce greater immunological restitution by an increased reduction in proviral DNA compared to NNRTI regimens (Llibre and Martínez-Picado, 2008; Villanueva-Millán et al., 2017; Ray et al., 2021).

Study Limitations

Because the study HIV study participants received treatment with both ART and prophylactic cotrimoxazole, we cannot differentiate how these drugs impact diversity individually. Although it is tempting to speculate that these differences observed are driven by long-term antibiotic use, the multifactorial nature of HIV management makes it difficult to identify which disease or treatment aspects are driving the microbiome changes.

It is also possible that our limited sample size was underpowered to detect a difference where one existed. Given the complexity of the microbiome, we suggest future microbiota studies in HIV disease should be designed to minimise the influence of confounders and address environmental factors.

Conclusion

In summary, our findings on the early impact on the gut microbiota in HIV-infected individuals initiating daily prophylaxis show a gradual reduction in diversity, with the most significant change after day 5. We also observed a composition shift characterised by the enrichment of species belonging to the *Prevetollea* and *Ruminococcus* genera and the depletion of species belonging to the Lactococcus and Bacteroides genera. These changes occur within five days and last well beyond 30 days post-initiation. This trend and significant shifts in functional microbial communities suggest an early onset of dysbiosis following TMP/SXT initiations. Further studies are needed to investigate the myriad of factors associated with HIV by leveraging a more robust multi-omics approach to offer a guide for future exploration of the effects of daily antibiotics during HIV disease.

Acknowledgements

We want to thank the staff of the Makerere Joint AIDS Project Clinic at Mulago Hospital: Moses M. Luutu and the team of the Molecular laboratory at Makerere University for technical support.

Funding

The study was supported by the US NIH – Fogarty International Center grant entitled "Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda" (MITHU, Grant #D43TW010319) and in part supported by the Africa Centre of Excellence in Materials, Product Development & Nanotechnology (MAPRONANO) (Project ID Number: P151847, IDA Number; 5797-UG). The funders had no role in the study design, data collection, analysis, publication decision, or manuscript preparation.

Author contributions

CAA, CFN & BA conceived the study, and CAA and DPK designed the experiments. CAA performed experiments, and CAA, AM, KE & SM analysed the data. CAA, MA, and BA interpreted the data and wrote the paper. All authors reviewed and edited the manuscript.

Availability of data and material

Raw sequences and study metadata generated during the study are available in the NCBI SRA repository <u>https://www.ncbi.nlm.nih.gov/bioproject/</u>.

Competing interests

The authors declare that they have no competing interests.

References

D'Souza, A. W. *et al.* (2020) 'Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α -Diversity but Decreases β -Diversity in the Gut Microbiome of Human Immunodeficiency Virus-Exposed, Uninfected Infants', *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 71(11), pp. 2858–2868. doi: 10.1093/cid/ciz1186.

Dai, Z.-L., Wu, G. and Zhu, W.-Y. (2011) 'Amino acid metabolism in intestinal bacteria: links between gut ecology and host health.', *Frontiers in bioscience (Landmark edition)*, 16(5), pp. 1768–1786. doi: 10.2741/3820.

Dillon, S. M. *et al.* (2014) 'An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia', *Mucosal Immunology*, 7(4), pp. 983–994. doi: 10.1038/mi.2013.116.

Dillon, S. M., Frank, D. N. and Wilson, C. C. (2016) 'The gut microbiome and HIV-1 pathogenesis: a two-way street', *AIDS (London, England)*, 30(18), pp. 2737–2751. doi: 10.1097/QAD.00000000001289.

Flint, H. J. *et al.* (2008) 'Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis.', *Nature reviews. Microbiology*, 6(2), pp. 121–131. doi: 10.1038/nrmicro1817.

Franzosa, E. A. *et al.* (2018) 'Species-level functional profiling of metagenomes and metatranscriptomes.', *Nature methods*, 15(11), pp. 962–968. doi: 10.1038/s41592-018-0176-y.

Holmes, C. B. *et al.* (2003) 'Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa.', *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 36(5), pp. 652–662. doi: 10.1086/367655.

Jiang, F. *et al.* (2017) 'The symbiotic bacterial surface factor polysaccharide A on Bacteroides fragilis inhibits IL-1β-induced inflammation in human fetal enterocytes via toll receptors 2 and 4.', *PloS one*, 12(3), p. e0172738. doi: 10.1371/journal.pone.0172738.

Kaplan, J. E. *et al.* (1996) 'Preventing opportunistic infections in human immunodeficiency virusinfected persons: implications for the developing world.', *The American journal of tropical medicine and hygiene*, 55(1), pp. 1–11. Kau, A. L. *et al.* (2011) 'Human nutrition, the gut microbiome and the immune system.', *Nature*, 474(7351), pp. 327–336. doi: 10.1038/nature10213.

Kaur, U. S. *et al.* (2018) 'High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy', *Scientific Reports*, 8(1), p. 17679. doi: 10.1038/s41598-018-35877-4.

Lee, S. C. *et al.* (2018) 'Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals', *Scientific Reports*, 8(1), p. 14277. doi: 10.1038/s41598-018-32585-x.

Liu, J. *et al.* (2017) 'Inside Out: HIV, the Gut Microbiome, and the Mucosal Immune System.', *Journal of immunology (Baltimore, Md. : 1950)*, 198(2), pp. 605–614. doi: 10.4049/jimmunol.1601355.

Llibre, J. M. and Martínez-Picado, J. (2008) '[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].', *Enfermedades infecciosas y microbiologia clinica*, 26 Suppl 1, pp. 17–22. doi: 10.1016/s0213-005x(08)76568-6.

Lowe, D. M. *et al.* (2013) 'Pneumocystis jirovecii Pneumonia in Tropical and Low and Middle Income Countries: A Systematic Review and Meta-Regression', *PLoS ONE*. Edited by S. H. Vermund, 8(8), p. e69969. doi: 10.1371/journal.pone.0069969.

Lozupone, C. A. *et al.* (2014) 'HIV-induced alteration in gut Microbiota: Driving factors, consequences, and effects of antiretroviral therapy', *Gut Microbes*, 5(4), pp. 562–570. doi: 10.4161/gmic.32132.

Lu, W. *et al.* (2018) 'Association between gut microbiota and CD4 recovery in HIV-1 infected patients', *Frontiers in Microbiology*, 9(JUL), pp. 1–10. doi: 10.3389/fmicb.2018.01451.

Lyu, W. *et al.* (2021) 'Gut lactate-producing bacteria promote CD4 T cell recovery on Anti-retroviral therapy in HIV-infected patients', *Computational and Structural Biotechnology Journal*, 19, pp. 2928–2937. doi: https://doi.org/10.1016/j.csbj.2021.05.021.

Machiavelli, A. *et al.* (2019) 'The impact of in utero HIV exposure on gut microbiota, inflammation, and microbial translocation', *Gut Microbes*, 10(5), pp. 599–614. doi: 10.1080/19490976.2018.1560768.

Mardis, E. R. (2008) 'Next-Generation DNA Sequencing Methods', *Annual Review of Genomics and Human Genetics*, 9(1), pp. 387–402. doi: 10.1146/annurev.genom.9.081307.164359.

McHardy, I. H. *et al.* (2013) 'HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota', *Microbiome*, 1(1), p. 26. doi: 10.1186/2049-2618-1-26.

Metges, C. C. (2000) 'Contribution of Microbial Amino Acids to Amino Acid Homeostasis of the Host', *The Journal of Nutrition*, 130(7), pp. 1857S-1864S. doi: 10.1093/jn/130.7.1857S.

Monaco, C. L. *et al.* (2016) 'Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome.', *Cell host & microbe*, 19(3), pp. 311–322. doi: 10.1016/j.chom.2016.02.011.

Mutlu, E. A. *et al.* (2014) 'A Compositional Look at the Human Gastrointestinal Microbiome and Immune Activation Parameters in HIV Infected Subjects', *PLoS Pathogens*. Edited by D. A. Relman, 10(2), p. e1003829. doi: 10.1371/journal.ppat.1003829.

Neff, C. P. *et al.* (2018) 'Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals.', *EBioMedicine*, 30, pp. 192–202. doi: 10.1016/j.ebiom.2018.03.024.

O'Neill, L. A. J., Kishton, R. J. and Rathmell, J. (2016) 'A guide to immunometabolism for immunologists.', *Nature reviews. Immunology*, 16(9), pp. 553–565. doi: 10.1038/nri.2016.70.

of Health, M. and Republic of Uganda, T. (2016) 'Ministry of Health CONSOLIDATED GUIDELINES FOR

PREVENTION AND TREATMENT OF HIV IN UGANDA', (September).

Palleja, A. *et al.* (2018) 'Recovery of gut microbiota of healthy adults following antibiotic exposure.', *Nature microbiology*, 3(11), pp. 1255–1265. doi: 10.1038/s41564-018-0257-9.

Parbie, P. K. *et al.* (2021) 'Dysbiotic Fecal Microbiome in HIV-1 Infected Individuals in Ghana.', *Frontiers in cellular and infection microbiology*, 11, p. 646467. doi: 10.3389/fcimb.2021.646467.

Pérez-Santiago, J. *et al.* (2013) 'Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.', *AIDS (London, England)*, 27(12), pp. 1921–1931. doi: 10.1097/qad.0b013e3283611816.

Png, C. W. *et al.* (2010) 'Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.', *The American journal of gastroenterology*, 105(11), pp. 2420–2428. doi: 10.1038/ajg.2010.281.

Ray, S. *et al.* (2021) 'Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine', *ACS Infectious Diseases*, 7(5), pp. 1104–1115. doi: 10.1021/acsinfecdis.0c00536.

Raymond, F. *et al.* (2016) 'The initial state of the human gut microbiome determines its reshaping by antibiotics.', *The ISME journal*, 10(3), pp. 707–720. doi: 10.1038/ismej.2015.148.

Russo, E. *et al.* (2022) 'Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.', *World journal of gastroenterology*, 28(6), pp. 635–652. doi: 10.3748/wjg.v28.i6.635.

Segata, N. *et al.* (2012) 'Metagenomic microbial community profiling using unique clade-specific marker genes', *Nature Methods*, 9(8), pp. 811–814. doi: 10.1038/nmeth.2066.

Shaw, L. P. *et al.* (2019) 'Modelling microbiome recovery after antibiotics using a stability landscape framework.', *The ISME journal*, 13(7), pp. 1845–1856. doi: 10.1038/s41396-019-0392-1.

Sheng, S. *et al.* (2021) 'Structural and Functional Alterations of Gut Microbiota in Males With Hyperuricemia and High Levels of Liver Enzymes.', *Frontiers in medicine*, 8, p. 779994. doi: 10.3389/fmed.2021.779994.

Stokes, J. M. *et al.* (2019) 'Bacterial Metabolism and Antibiotic Efficacy.', *Cell metabolism*, 30(2), pp. 251–259. doi: 10.1016/j.cmet.2019.06.009.

Thaiss, C. A. *et al.* (2016) 'The microbiome and innate immunity.', *Nature*, 535(7610), pp. 65–74. doi: 10.1038/nature18847.

Tremaroli, V. and Bäckhed, F. (2012) 'Functional interactions between the gut microbiota and host metabolism.', *Nature*, 489(7415), pp. 242–249. doi: 10.1038/nature11552.

Uritskiy, G. V, DiRuggiero, J. and Taylor, J. (2018) 'MetaWRAP—a flexible pipeline for genome-resolved metagenomic data analysis', *Microbiome*, 6(1), p. 158. doi: 10.1186/s40168-018-0541-1.

Villanueva-Millán, M. J. *et al.* (2017) 'Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients', *Journal of the International AIDS Society*, 20(1), pp. 1–13. doi: 10.7448/IAS.20.1.21526.

Vujkovic-Cvijin, I. *et al.* (2013) 'Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.', *Science translational medicine*, 5(193), p. 193ra91. doi: 10.1126/scitranslmed.3006438.

Vujkovic-Cvijin, I. and Somsouk, M. (2019) 'HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration.', *Current HIV/AIDS reports*, 16(3), pp. 204–213. doi: 10.1007/s11904-019-00441-w.

Weinberg, J. L. and Kovarik, C. L. (2010) 'The WHO clinical staging system for HIV/AIDS', Virtual

Mentor, 12(3), pp. 202–206. doi: 10.1001/virtualmentor.2010.12.3.cprl1-1003.

WHO (2014) 'The use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children', *2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection*, (7), pp. 28–34. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/December2014-ARVsupplement-chap8.pdf%5Cnhttp://www.who.int/hiv/pub/guidelines/arv2013/en/.

Xie, Y. *et al.* (2021) 'Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals', *BMC Microbiology*, 21(1), p. 11. doi: 10.1186/s12866-020-02074-1.

Yan Yang, S. *et al.* (2016) 'Lactococcus nasutitermitis sp. nov. isolated from a termite gut.', *International journal of systematic and evolutionary microbiology*, 66(1), pp. 518–522. doi: 10.1099/ijsem.0.000743.

Zevin, A. S. *et al.* (2016) 'Microbial translocation and microbiome dysbiosis in HIV-associated immune activation.', *Current opinion in HIV and AIDS*, 11(2), pp. 182–190. doi: 10.1097/COH.00000000000234.

D'Souza, A. W. *et al.* (2020) 'Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α -Diversity but Decreases β -Diversity in the Gut Microbiome of Human Immunodeficiency Virus-Exposed, Uninfected Infants', *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 71(11), pp. 2858–2868. doi: 10.1093/cid/ciz1186.

Dai, Z.-L., Wu, G. and Zhu, W.-Y. (2011) 'Amino acid metabolism in intestinal bacteria: links between gut ecology and host health.', *Frontiers in bioscience (Landmark edition)*, 16(5), pp. 1768–1786. doi: 10.2741/3820.

Dillon, S. M. *et al.* (2014) 'An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia', *Mucosal Immunology*, 7(4), pp. 983–994. doi: 10.1038/mi.2013.116.

Dillon, S. M., Frank, D. N. and Wilson, C. C. (2016) 'The gut microbiome and HIV-1 pathogenesis: a two-way street', *AIDS (London, England)*, 30(18), pp. 2737–2751. doi: 10.1097/QAD.00000000001289.

Flint, H. J. *et al.* (2008) 'Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis.', *Nature reviews. Microbiology*, 6(2), pp. 121–131. doi: 10.1038/nrmicro1817.

Franzosa, E. A. *et al.* (2018) 'Species-level functional profiling of metagenomes and metatranscriptomes.', *Nature methods*, 15(11), pp. 962–968. doi: 10.1038/s41592-018-0176-y.

Holmes, C. B. *et al.* (2003) 'Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa.', *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 36(5), pp. 652–662. doi: 10.1086/367655.

Jiang, F. *et al.* (2017) 'The symbiotic bacterial surface factor polysaccharide A on Bacteroides fragilis inhibits IL-1β-induced inflammation in human fetal enterocytes via toll receptors 2 and 4.', *PloS one*, 12(3), p. e0172738. doi: 10.1371/journal.pone.0172738.

Kaplan, J. E. *et al.* (1996) 'Preventing opportunistic infections in human immunodeficiency virusinfected persons: implications for the developing world.', *The American journal of tropical medicine and hygiene*, 55(1), pp. 1–11.

Kau, A. L. *et al.* (2011) 'Human nutrition, the gut microbiome and the immune system.', *Nature*, 474(7351), pp. 327–336. doi: 10.1038/nature10213.

Kaur, U. S. et al. (2018) 'High Abundance of genus Prevotella in the gut of perinatally HIV-infected

children is associated with IP-10 levels despite therapy', *Scientific Reports*, 8(1), p. 17679. doi: 10.1038/s41598-018-35877-4.

Lee, S. C. *et al.* (2018) 'Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals', *Scientific Reports*, 8(1), p. 14277. doi: 10.1038/s41598-018-32585-x.

Liu, J. *et al.* (2017) 'Inside Out: HIV, the Gut Microbiome, and the Mucosal Immune System.', *Journal of immunology (Baltimore, Md. : 1950)*, 198(2), pp. 605–614. doi: 10.4049/jimmunol.1601355.

Llibre, J. M. and Martínez-Picado, J. (2008) '[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].', *Enfermedades infecciosas y microbiologia clinica*, 26 Suppl 1, pp. 17–22. doi: 10.1016/s0213-005x(08)76568-6.

Lowe, D. M. *et al.* (2013) 'Pneumocystis jirovecii Pneumonia in Tropical and Low and Middle Income Countries: A Systematic Review and Meta-Regression', *PLoS ONE*. Edited by S. H. Vermund, 8(8), p. e69969. doi: 10.1371/journal.pone.0069969.

Lozupone, C. A. *et al.* (2014) 'HIV-induced alteration in gut Microbiota: Driving factors, consequences, and effects of antiretroviral therapy', *Gut Microbes*, 5(4), pp. 562–570. doi: 10.4161/gmic.32132.

Lu, W. *et al.* (2018) 'Association between gut microbiota and CD4 recovery in HIV-1 infected patients', *Frontiers in Microbiology*, 9(JUL), pp. 1–10. doi: 10.3389/fmicb.2018.01451.

Lyu, W. *et al.* (2021) 'Gut lactate-producing bacteria promote CD4 T cell recovery on Anti-retroviral therapy in HIV-infected patients', *Computational and Structural Biotechnology Journal*, 19, pp. 2928–2937. doi: https://doi.org/10.1016/j.csbj.2021.05.021.

Machiavelli, A. *et al.* (2019) 'The impact of in utero HIV exposure on gut microbiota, inflammation, and microbial translocation', *Gut Microbes*, 10(5), pp. 599–614. doi: 10.1080/19490976.2018.1560768.

Mardis, E. R. (2008) 'Next-Generation DNA Sequencing Methods', *Annual Review of Genomics and Human Genetics*, 9(1), pp. 387–402. doi: 10.1146/annurev.genom.9.081307.164359.

McHardy, I. H. *et al.* (2013) 'HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota', *Microbiome*, 1(1), p. 26. doi: 10.1186/2049-2618-1-26.

Metges, C. C. (2000) 'Contribution of Microbial Amino Acids to Amino Acid Homeostasis of the Host', *The Journal of Nutrition*, 130(7), pp. 1857S-1864S. doi: 10.1093/jn/130.7.1857S.

Monaco, C. L. *et al.* (2016) 'Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome.', *Cell host & microbe*, 19(3), pp. 311–322. doi: 10.1016/j.chom.2016.02.011.

Mutlu, E. A. *et al.* (2014) 'A Compositional Look at the Human Gastrointestinal Microbiome and Immune Activation Parameters in HIV Infected Subjects', *PLoS Pathogens*. Edited by D. A. Relman, 10(2), p. e1003829. doi: 10.1371/journal.ppat.1003829.

Neff, C. P. *et al.* (2018) 'Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals.', *EBioMedicine*, 30, pp. 192–202. doi: 10.1016/j.ebiom.2018.03.024.

O'Neill, L. A. J., Kishton, R. J. and Rathmell, J. (2016) 'A guide to immunometabolism for immunologists.', *Nature reviews. Immunology*, 16(9), pp. 553–565. doi: 10.1038/nri.2016.70.

of Health, M. and Republic of Uganda, T. (2016) 'Ministry of Health CONSOLIDATED GUIDELINES FOR PREVENTION AND TREATMENT OF HIV IN UGANDA', (September).

Palleja, A. *et al.* (2018) 'Recovery of gut microbiota of healthy adults following antibiotic exposure.', *Nature microbiology*, 3(11), pp. 1255–1265. doi: 10.1038/s41564-018-0257-9.

It is made available under a CC-BY 4.0 International license .

Parbie, P. K. *et al.* (2021) 'Dysbiotic Fecal Microbiome in HIV-1 Infected Individuals in Ghana.', *Frontiers in cellular and infection microbiology*, 11, p. 646467. doi: 10.3389/fcimb.2021.646467.

Pérez-Santiago, J. *et al.* (2013) 'Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.', *AIDS (London, England)*, 27(12), pp. 1921–1931. doi: 10.1097/qad.0b013e3283611816.

Png, C. W. *et al.* (2010) 'Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.', *The American journal of gastroenterology*, 105(11), pp. 2420–2428. doi: 10.1038/ajg.2010.281.

Ray, S. *et al.* (2021) 'Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine', *ACS Infectious Diseases*, 7(5), pp. 1104–1115. doi: 10.1021/acsinfecdis.0c00536.

Raymond, F. *et al.* (2016) 'The initial state of the human gut microbiome determines its reshaping by antibiotics.', *The ISME journal*, 10(3), pp. 707–720. doi: 10.1038/ismej.2015.148.

Russo, E. *et al.* (2022) 'Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.', *World journal of gastroenterology*, 28(6), pp. 635–652. doi: 10.3748/wjg.v28.i6.635.

Segata, N. *et al.* (2012) 'Metagenomic microbial community profiling using unique clade-specific marker genes', *Nature Methods*, 9(8), pp. 811–814. doi: 10.1038/nmeth.2066.

Shaw, L. P. *et al.* (2019) 'Modelling microbiome recovery after antibiotics using a stability landscape framework.', *The ISME journal*, 13(7), pp. 1845–1856. doi: 10.1038/s41396-019-0392-1.

Sheng, S. *et al.* (2021) 'Structural and Functional Alterations of Gut Microbiota in Males With Hyperuricemia and High Levels of Liver Enzymes.', *Frontiers in medicine*, 8, p. 779994. doi: 10.3389/fmed.2021.779994.

Stokes, J. M. *et al.* (2019) 'Bacterial Metabolism and Antibiotic Efficacy.', *Cell metabolism*, 30(2), pp. 251–259. doi: 10.1016/j.cmet.2019.06.009.

Thaiss, C. A. *et al.* (2016) 'The microbiome and innate immunity.', *Nature*, 535(7610), pp. 65–74. doi: 10.1038/nature18847.

Tremaroli, V. and Bäckhed, F. (2012) 'Functional interactions between the gut microbiota and host metabolism.', *Nature*, 489(7415), pp. 242–249. doi: 10.1038/nature11552.

Uritskiy, G. V, DiRuggiero, J. and Taylor, J. (2018) 'MetaWRAP—a flexible pipeline for genome-resolved metagenomic data analysis', *Microbiome*, 6(1), p. 158. doi: 10.1186/s40168-018-0541-1.

Villanueva-Millán, M. J. *et al.* (2017) 'Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients', *Journal of the International AIDS Society*, 20(1), pp. 1–13. doi: 10.7448/IAS.20.1.21526.

Vujkovic-Cvijin, I. *et al.* (2013) 'Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.', *Science translational medicine*, 5(193), p. 193ra91. doi: 10.1126/scitranslmed.3006438.

Vujkovic-Cvijin, I. and Somsouk, M. (2019) 'HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration.', *Current HIV/AIDS reports*, 16(3), pp. 204–213. doi: 10.1007/s11904-019-00441-w.

Weinberg, J. L. and Kovarik, C. L. (2010) 'The WHO clinical staging system for HIV/AIDS', *Virtual Mentor*, 12(3), pp. 202–206. doi: 10.1001/virtualmentor.2010.12.3.cprl1-1003.

WHO (2014) 'The use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children', 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, (7), pp. 28–34. Available at:

http://www.who.int/hiv/pub/guidelines/arv2013/December2014-ARVsupplementchap8.pdf%5Cnhttp://www.who.int/hiv/pub/guidelines/arv2013/en/.

Xie, Y. *et al.* (2021) 'Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals', *BMC Microbiology*, 21(1), p. 11. doi: 10.1186/s12866-020-02074-1.

Yan Yang, S. *et al.* (2016) 'Lactococcus nasutitermitis sp. nov. isolated from a termite gut.', *International journal of systematic and evolutionary microbiology*, 66(1), pp. 518–522. doi: 10.1099/ijsem.0.000743.

Zevin, A. S. *et al.* (2016) 'Microbial translocation and microbiome dysbiosis in HIV-associated immune activation.', *Current opinion in HIV and AIDS*, 11(2), pp. 182–190. doi: 10.1097/COH.0000000000234.